1 Paul Revere Road
Needham MA 02494
USA
Phone: +1 (312) 209-2001
Website: https://www.catailyst.ai
Email: hello@catailyst.ai
General Information:
Catailyst has combined automation and artificial intelligence to understand scientific, clinical and business announcements from various public information sources, such as press releases, SEC filings, and trial registrations to create actionable and searchable data points. Catailyst has recently launched a database and data analytics platform to provide access to such data. The company has also developed several real-time alerts.
Catailyst aims to provide this data to its customers from a cloud based platform with SAAS (software as a service) subscription business model. The company brings a comprehensive solution for Biotech and Pharma business development teams, clinical development team, investment bankers, investors, and life science consultants to track drug development, monitor competition, follow market trends and inform about recent developments of drug candidates and approved drugs.
Catailyst has developed many proprietary methods of artificial intelligence involving machine learning and natural language processing methods to read and analyze different forms of texts announced daily such as press releases, SEC filings and trial registrations. Catailyst was in stealth for the last three years and during this time the company has developed several methods of artificial intelligence. A patent related to such invention was filed to USPTO in 2020 and the company filed PCT applications in certain countries from EU, Canada and India. No patents have been granted.
Catailyst has added business process automation to its artificial intelligence and enabled methods of identifying, extracting and categorizing relevant data points without human intervention. By implementing such a process, the Company processes 500+ press releases, 100+ clinical trials related information, and hundreds of SEC filings everyday.